A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
- 27 October 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 29 (2), 304-313
- https://doi.org/10.1016/j.vaccine.2010.10.037
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus MonkeysJournal of Virology, 2009
- Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humansNature Medicine, 2009
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challengeVirology, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Comparison of multiple vaccine vectors in a single heterologous prime-boost trialVaccine, 2008
- Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene InsertsJournal of Immunotoxicology, 2008
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate VaccineThe Journal of Infectious Diseases, 2006
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006